US6022950A
(en)
*
|
1984-06-07 |
2000-02-08 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
US5668255A
(en)
*
|
1984-06-07 |
1997-09-16 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
US5169939A
(en)
*
|
1985-05-21 |
1992-12-08 |
Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College |
Chimeric antibodies
|
US6051405A
(en)
*
|
1986-09-24 |
2000-04-18 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Constructs encoding recombinant antibody-toxin fusion proteins
|
US4892827A
(en)
*
|
1986-09-24 |
1990-01-09 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
|
EP0422049A4
(en)
*
|
1988-05-09 |
1991-11-13 |
Us Health |
Vector for secretion of proteins directly into periplasm or culture medium
|
US5206353A
(en)
*
|
1988-07-23 |
1993-04-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
CD-4/cytotoxic gene fusions
|
US5135736A
(en)
*
|
1988-08-15 |
1992-08-04 |
Neorx Corporation |
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
|
US5169933A
(en)
*
|
1988-08-15 |
1992-12-08 |
Neorx Corporation |
Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
|
US5149782A
(en)
*
|
1988-08-19 |
1992-09-22 |
Tanox Biosystems, Inc. |
Molecular conjugates containing cell membrane-blending agents
|
ZA898139B
(en)
*
|
1988-11-17 |
1990-08-29 |
Hoffmann La Roche |
Recombinant interleukin-2 hybrid proteins
|
ES2085329T3
(es)
*
|
1989-02-17 |
1996-06-01 |
Merck & Co Inc |
Agente anticanceroso proteico.
|
US6406697B1
(en)
*
|
1989-02-23 |
2002-06-18 |
Genentech, Inc. |
Hybrid immunoglobulins
|
IL93723A
(en)
*
|
1989-03-22 |
1997-02-18 |
Merck & Co Inc |
Cystein modified truncated pseudomonas exotoxin A
|
US5621078A
(en)
*
|
1989-03-22 |
1997-04-15 |
Merck & Co., Inc. |
Modified pseudomonas exotoxin PE40
|
ES2091824T3
(es)
*
|
1989-04-21 |
1996-11-16 |
Us Health |
Proteina recombinante de fusion toxina anticuerpo.
|
US6207798B1
(en)
|
1989-08-03 |
2001-03-27 |
Merck & Co., Inc. |
Modified PE40 toxin fusion proteins
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
WO1991009965A1
(en)
*
|
1989-12-21 |
1991-07-11 |
The United States Of America, Represented By The Secretary, United States Department Of Commerce |
An improved toxin for construction of immunotoxins
|
EP0509056A4
(en)
*
|
1990-01-02 |
1993-02-17 |
Us Health |
Target-specific, cytotoxic, recombinant pseudomonas exotoxin
|
US5458878A
(en)
*
|
1990-01-02 |
1995-10-17 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
|
US5110912A
(en)
*
|
1990-03-02 |
1992-05-05 |
Seragen, Inc. |
Purification of il-2-containing hybrid compounds
|
AU646673B2
(en)
*
|
1990-05-11 |
1994-03-03 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity
|
IL98528A0
(en)
*
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
US5241053A
(en)
*
|
1990-09-05 |
1993-08-31 |
Takeda Chemical Industries, Ltd. |
Fused proteins comprising glycoprotein gD of HSV-1 and LTB
|
US6099842A
(en)
*
|
1990-12-03 |
2000-08-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
|
US5571894A
(en)
*
|
1991-02-05 |
1996-11-05 |
Ciba-Geigy Corporation |
Recombinant antibodies specific for a growth factor receptor
|
JPH05509234A
(ja)
*
|
1991-02-08 |
1993-12-22 |
ルセル ユクラフ |
ヒトTリンパ球レセプターのα鎖の可変領域をコードするヌクレオチド配列対応するペプチドセグメント並びに診断及び治療への利用
|
FR2672616B1
(fr)
*
|
1991-02-08 |
1994-09-23 |
Roussel Uclaf |
Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs de lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques.
|
IE920447A1
(en)
*
|
1991-02-12 |
1992-08-12 |
Roussel Uclaf |
NUCLEOTIDE SEQUENCES CODING FOR ß-CHAIN VARIABLE REGIONS OF¹HUMAN T-LYMPHOCYTE RECEPTORS, CORRESPONDING PEPTIDE SEGMENTS¹AND DIAGNOSTIC AND THERAPEUTIC APPLICATIONS
|
US5328984A
(en)
*
|
1991-03-04 |
1994-07-12 |
The United States As Represented By The Department Of Health & Human Services |
Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
|
US5223604A
(en)
*
|
1991-06-25 |
1993-06-29 |
S.P.I. Synthetic Peptides Incorporated |
Pseudomonas exoenzyme s peptide composition and method
|
US5939531A
(en)
*
|
1991-07-15 |
1999-08-17 |
Novartis Corp. |
Recombinant antibodies specific for a growth factor receptor
|
CA2081952A1
(en)
*
|
1991-11-08 |
1993-05-09 |
John J. Donnelly |
Recombinant dna sequences and plasmids for cellular immunity vaccines from bacterial toxin-antigen conjugates, and methods of their use
|
WO1993025690A1
(en)
*
|
1992-06-18 |
1993-12-23 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Recombinant pseudomonas exotoxin with increased activity
|
GB9326174D0
(en)
*
|
1993-12-22 |
1994-02-23 |
Biocine Sclavo |
Mucosal adjuvant
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
WO1997013529A1
(en)
*
|
1995-10-13 |
1997-04-17 |
The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services |
Immunotoxin containing a disulfide-stabilized antibody fragment
|
KR100498198B1
(ko)
|
1996-03-01 |
2005-09-09 |
노파르티스 아게 |
알레르기에 대한 백신접종 및 치료를 위한 펩티드 임뮤노겐
|
US6426075B1
(en)
|
1996-11-06 |
2002-07-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Protease-activatable pseudomonas exotoxin A-like proproteins
|
US6818222B1
(en)
|
1997-03-21 |
2004-11-16 |
Chiron Corporation |
Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
|
US20030198772A1
(en)
*
|
1997-06-26 |
2003-10-23 |
Weder Donald E. |
Polymeric materials having a texture or appearance simulating the texture or appearance of paper
|
US20020004113A1
(en)
*
|
1997-06-26 |
2002-01-10 |
Weder Donald E. |
Decorative cover for flower pot or floral grouping formed of polymeric materials having a texture or appearance simulating the texture or appearance of paper
|
US20030054012A1
(en)
*
|
2000-05-12 |
2003-03-20 |
Fitzgerald David J. |
Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
|
JP2001510683A
(ja)
*
|
1997-07-11 |
2001-08-07 |
ザ ガバメント オブ ザ ユナイテッド ステイツ リプリゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Pseudomonas体外毒素A様キメラ免疫原
|
US7314632B1
(en)
*
|
1997-07-11 |
2008-01-01 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pseudomonas exotoxin A-like chimeric immunogens
|
US6077676A
(en)
*
|
1997-12-18 |
2000-06-20 |
Spectral Diagnostics, Inc. |
Single-chain polypeptides comprising troponin I and troponin C
|
AU2004201055B2
(en)
*
|
1998-04-24 |
2007-08-23 |
The Regents Of The University Of California |
Internalizing ErbB2 antibodies
|
US6794128B2
(en)
*
|
1998-04-24 |
2004-09-21 |
The Regents Of The University Of California |
Methods of selecting internalizing antibodies
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
US20020142000A1
(en)
*
|
1999-01-15 |
2002-10-03 |
Digan Mary Ellen |
Anti-CD3 immunotoxins and therapeutic uses therefor
|
US20030143233A1
(en)
*
|
1999-06-07 |
2003-07-31 |
Neorx Corporation |
Streptavidin expressed gene fusions and methods of use thereof
|
US20030103948A1
(en)
*
|
1999-06-07 |
2003-06-05 |
Neorx Corporation |
Streptavidin expressed gene fusions and methods of use thereof
|
US7144991B2
(en)
|
1999-06-07 |
2006-12-05 |
Aletheon Pharmaceuticals, Inc. |
Streptavidin expressed gene fusions and methods of use thereof
|
US6838553B1
(en)
*
|
1999-10-05 |
2005-01-04 |
Academia Sinica |
Peptide repeat immunogens
|
US7078486B2
(en)
*
|
1999-12-10 |
2006-07-18 |
Spectral Diagnostics, Inc. |
Single-chain polypeptides comprising troponin I and troponin C
|
CA2410024A1
(en)
*
|
2000-04-25 |
2001-11-01 |
The Board Of Regents Of The University Oklahoma |
Identification and uses of a hyaluronan receptor
|
US20050287638A1
(en)
*
|
2000-04-25 |
2005-12-29 |
Weigel Paul H |
Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same
|
DE60137969D1
(de)
*
|
2000-12-21 |
2009-04-23 |
Us Gov Health & Human Serv |
Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält
|
WO2002086093A2
(en)
*
|
2001-04-25 |
2002-10-31 |
Weigel Paul H |
Methods of using a hyaluronan receptor
|
CA2461351C
(en)
|
2001-09-26 |
2014-08-05 |
Ira H. Pastan |
Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells
|
IL161863A0
(en)
*
|
2001-11-09 |
2005-11-20 |
Neopharm Inc |
Selective treatment of il-13 expressing tumors
|
WO2004087758A2
(en)
*
|
2003-03-26 |
2004-10-14 |
Neopharm, Inc. |
Il 13 receptor alpha 2 antibody and methods of use
|
US20070196366A1
(en)
|
2003-04-30 |
2007-08-23 |
Uwe Zangemeister-Wittke |
Methods for treating cancer using an immunotoxin
|
CA2547165C
(en)
|
2003-11-25 |
2014-07-08 |
Ira H. Pastan |
Mutated anti-cd22 antibodies and immunoconjugates
|
WO2006039238A2
(en)
*
|
2004-09-30 |
2006-04-13 |
The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Irta2 antibodies and methods of use
|
US7611714B2
(en)
|
2004-10-04 |
2009-11-03 |
Trinity Biosystems, Inc. |
Methods and compositions for immunizing against Pseudomonas infection
|
CA2583202A1
(en)
*
|
2004-10-04 |
2006-04-27 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of macromolecules
|
WO2006069331A2
(en)
|
2004-12-22 |
2006-06-29 |
The Salk Institute For Biological Studies |
Compositions and methods for producing recombinant proteins
|
AU2006247188A1
(en)
|
2005-05-18 |
2006-11-23 |
Children's Hospital & Research Center At Oakland |
Methods and compositions for immunizing against chlamydia infection
|
ES2702650T3
(es)
|
2005-07-29 |
2019-03-04 |
The Government Of The Us Secretary Of Health And Human Services |
Exotoxinas de pseudomonas mutadas con antigenicidad reducida
|
CA2631981A1
(en)
*
|
2005-12-05 |
2007-06-14 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of binding partners
|
WO2007067596A2
(en)
*
|
2005-12-05 |
2007-06-14 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of antibodies
|
EP2010205A2
(en)
*
|
2006-03-16 |
2009-01-07 |
Trinity Biosystems, Inc. |
Methods for increasing the size of animals using needleless delivery constructs
|
EP1878744A1
(en)
*
|
2006-07-13 |
2008-01-16 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC) |
Epitope-tag for surface-expressed T-cell receptor proteins, uses thereof and method of selecting host cells expressing them
|
US20090092660A1
(en)
*
|
2006-08-09 |
2009-04-09 |
Trinity Biosystems, Inc. |
Methods and compositions for needleless delivery of particles
|
JP2010534061A
(ja)
|
2007-07-20 |
2010-11-04 |
ザ ジェネラル ホスピタル コーポレイション |
組換えコレラ菌外毒素
|
AU2008296194B2
(en)
*
|
2007-09-04 |
2013-03-14 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Deletions in domain II of Pseudomonas exotoxin A that reduce non-specific toxicity
|
CN108129573B
(zh)
|
2007-09-21 |
2021-10-08 |
加利福尼亚大学董事会 |
被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
|
US8476410B2
(en)
|
2008-10-16 |
2013-07-02 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
|
WO2011031441A1
(en)
|
2009-08-28 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Therapy with a chimeric molecule and a pro-apoptotic agent
|
WO2011032022A1
(en)
|
2009-09-11 |
2011-03-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Improved pseudomonas exotoxin a with reduced immunogenicity
|
WO2011100455A1
(en)
|
2010-02-12 |
2011-08-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Inhibition of antibody responses to foreign proteins
|
AU2011238711B2
(en)
|
2010-03-30 |
2015-06-18 |
Pelican Technology Holdings, Inc. |
High level expression of recombinant toxin proteins
|
EP3135692B8
(en)
|
2010-06-16 |
2019-03-20 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Antibodies to endoplasmin and their use
|
LT3434346T
(lt)
|
2010-07-30 |
2020-12-28 |
Medimmune, Llc |
Išgryninti veiklūs polipeptidai ar imunokonjugatai
|
US11246915B2
(en)
|
2010-09-15 |
2022-02-15 |
Applied Molecular Transport Inc. |
Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
|
TWI689314B
(zh)
*
|
2010-11-30 |
2020-04-01 |
建南德克公司 |
低親和力血腦障壁受體抗體及其用途
|
CN105968209B
(zh)
|
2011-04-19 |
2021-08-03 |
美国政府(由卫生和人类服务部的部长所代表) |
对磷脂酰肌醇蛋白聚糖3特异的人单克隆抗体及其用途
|
CA2838013C
(en)
|
2011-06-09 |
2023-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes
|
US8932586B2
(en)
|
2011-09-06 |
2015-01-13 |
Intrexon Corporation |
Modified forms of Pseudomonas exotoxin A
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
ES2656505T3
(es)
|
2011-09-16 |
2018-02-27 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Exotoxina A de Pseudomonas con epítopos de linfocitos B menos inmunogénicos
|
EP2764025B1
(en)
|
2011-10-04 |
2017-11-29 |
IGEM Therapeutics Limited |
Ige-antibodies against hmw-maa
|
US9169304B2
(en)
|
2012-05-01 |
2015-10-27 |
Pfenex Inc. |
Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
|
SG11201407972RA
(en)
|
2012-06-01 |
2015-01-29 |
Us Health |
High-affinity monoclonal antibodies to glypican-3 and use thereof
|
EP2888282B1
(en)
|
2012-08-21 |
2018-03-14 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Mesothelin domain-specific monoclonal antibodies and use thereof
|
US9416190B2
(en)
|
2012-09-27 |
2016-08-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Mesothelin antibodies and methods for eliciting potent antitumor activity
|
US9803021B2
(en)
|
2012-12-07 |
2017-10-31 |
The Regents Of The University Of California |
CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
|
WO2014093240A1
(en)
|
2012-12-10 |
2014-06-19 |
The General Hospital Corporation |
Bivalent il-2 fusion toxins
|
JP6553515B2
(ja)
|
2012-12-20 |
2019-07-31 |
メディミューン,エルエルシー |
免疫複合体の製造方法
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
WO2014194100A1
(en)
|
2013-05-29 |
2014-12-04 |
The Regents Of The University Of California |
Anti-cspg4 fusions with interferon for the treatment of malignancy
|
CA2926215A1
(en)
|
2013-10-06 |
2015-04-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modified pseudomonas exotoxin a
|
WO2015054691A2
(en)
|
2013-10-11 |
2015-04-16 |
The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services |
Tem8 antibodies and their use
|
EP3066118B1
(en)
|
2013-11-06 |
2020-01-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
US10246505B2
(en)
|
2013-11-25 |
2019-04-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptors to control HIV infection
|
CA2937524A1
(en)
|
2014-02-05 |
2015-08-13 |
Molecular Templates, Inc. |
Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
|
CN106470707A
(zh)
|
2014-05-07 |
2017-03-01 |
应用分子运输有限责任公司 |
用于口服递送生物活性货物的cholix毒素衍生的融合分子
|
CN106999578B
(zh)
|
2014-07-31 |
2022-03-04 |
美国政府(由卫生和人类服务部的部长所代表) |
针对epha4的人类单克隆抗体和其用途
|
JP6613304B2
(ja)
|
2014-09-17 |
2019-12-04 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
抗cd276抗体(b7h3)
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
CA2981509A1
(en)
|
2015-03-30 |
2016-10-06 |
The Board Of Regents Of The Nevada System Of Higher Educ. On Behalf Of The University Of Nevada, La |
Compositions comprising talens and methods of treating hiv
|
US20180161429A1
(en)
|
2015-06-26 |
2018-06-14 |
Beth Israel Deaconess Medical Center Inc. |
Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
|
CA3000591A1
(en)
|
2015-10-13 |
2017-04-20 |
Sanofi Pasteur |
Immunogenic compositions against s. aureus
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
CN108473575B
(zh)
|
2015-11-13 |
2022-04-19 |
美国卫生和人力服务部 |
抗-bcma多肽和蛋白质
|
WO2017196847A1
(en)
|
2016-05-10 |
2017-11-16 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
|
WO2017214182A1
(en)
|
2016-06-07 |
2017-12-14 |
The United States Of America. As Represented By The Secretary, Department Of Health & Human Services |
Fully human antibody targeting pdi for cancer immunotherapy
|
US11066479B2
(en)
|
2016-08-02 |
2021-07-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
|
AU2017382883A1
(en)
|
2016-12-21 |
2019-06-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies specific for FLT3 and uses thereof
|
US11390683B2
(en)
|
2017-05-18 |
2022-07-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin polypeptides and proteins
|
AU2018268970A1
(en)
|
2017-05-19 |
2019-10-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
|
CA3066953A1
(en)
|
2017-06-30 |
2019-01-03 |
Lentigen Technology, Inc. |
Human monoclonal antibodies specific for cd33 and methods of their use
|
WO2019005208A1
(en)
|
2017-06-30 |
2019-01-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
|
US10849960B2
(en)
|
2017-09-08 |
2020-12-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
|
US11795235B2
(en)
|
2017-09-18 |
2023-10-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunotoxins with albumin binding domain
|
WO2019071150A1
(en)
|
2017-10-06 |
2019-04-11 |
University Of Utah Research Foundation |
FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE
|
SG11202009925PA
(en)
|
2018-03-08 |
2020-11-27 |
Applied Molecular Transport Inc |
Toxin-derived delivery constructs for oral delivery
|
JP7459043B2
(ja)
|
2018-07-12 |
2024-04-01 |
ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
親和性成熟cd22特異的モノクローナル抗体およびその使用
|
WO2020033430A1
(en)
|
2018-08-08 |
2020-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-2 and uses thereof
|
KR102353086B1
(ko)
*
|
2018-09-07 |
2022-01-20 |
아주대학교산학협력단 |
신규 면역독소 제조방법
|
IL282986B2
(en)
|
2018-11-07 |
2024-01-01 |
Applied Molecular Transport Inc |
Colics-derivative carriers for oral administration of heterologous cargo
|
ES2911075T3
(es)
|
2018-11-07 |
2022-05-17 |
Applied Molecular Transport Inc |
Constructos de administración para transcitosis y métodos relacionados
|
CN113490510A
(zh)
|
2019-01-08 |
2021-10-08 |
美国政府(由卫生和人类服务部的部长所代表) |
用于治疗实体瘤的靶向间皮素的跨物种单结构域抗体
|
AU2020212534A1
(en)
|
2019-01-22 |
2021-07-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
High affinity monoclonal antibodies targeting glypican-1 and methods of use
|
WO2020172344A1
(en)
|
2019-02-19 |
2020-08-27 |
The Regents Of The University Of Colorado, A Body Corporate |
Bispecific immunotoxins targeting human cd25+ccr4+ tumors and regulatory t-cells
|
CA3142833A1
(en)
|
2019-07-02 |
2021-01-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind egfrviii and their use
|
CA3150859A1
(en)
|
2019-08-16 |
2021-02-25 |
Applied Molecular Transport Inc. |
Compositions, formulations, and interleukin production and purification
|
US20220380471A1
(en)
|
2019-10-22 |
2022-12-01 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
High affinity nanobodies targeting b7-h3 (cd276) for treating multiple solid tumors
|
WO2021097289A1
(en)
|
2019-11-15 |
2021-05-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Pegylated recombinant immunotoxins
|
EP4110823A1
(en)
|
2020-02-26 |
2023-01-04 |
A2 Biotherapeutics, Inc. |
Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
|
US20230391852A1
(en)
|
2020-10-26 |
2023-12-07 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting sars coronavirus spike protein and uses thereof
|
CN116583539A
(zh)
|
2020-12-22 |
2023-08-11 |
江苏恒瑞医药股份有限公司 |
抗il-4r抗体或其抗原结合片段的复合物及医药用途
|
WO2022232612A1
(en)
|
2021-04-29 |
2022-11-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Lassa virus-specific nanobodies and methods of their use
|
EP4352099A1
(en)
|
2021-06-09 |
2024-04-17 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Cross species single domain antibodies targeting pd-l1 for treating solid tumors
|
WO2023076881A1
(en)
|
2021-10-26 |
2023-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
|
WO2023114980A1
(en)
|
2021-12-17 |
2023-06-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
|
WO2024050399A1
(en)
|
2022-09-01 |
2024-03-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
|